Get the Stockscreener App
0.7415
3.16%
-0.0242
After Hours:
.76
0.0185
+2.49%
Cue Biopharma Inc stock is traded at $0.7415, with a volume of 362.12K.
It is down -3.16% in the last 24 hours and down -6.14% over the past month.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
See More
Previous Close:
$0.7657
Open:
$0.765
24h Volume:
362.12K
Relative Volume:
1.23
Market Cap:
$56.98M
Revenue:
$9.53M
Net Income/Loss:
$-44.61M
P/E Ratio:
-0.8148
EPS:
-0.91
Net Cash Flow:
$-38.32M
1W Performance:
-4.94%
1M Performance:
-6.14%
6M Performance:
-26.58%
1Y Performance:
+27.84%
1-Day Range:
$0.72
$0.7779
1-Week Range:
$0.72
$0.79
52-Week Range:
$0.45
$1.9891
Cue Biopharma Inc Stock (CUE) Company Profile
Name
Cue Biopharma Inc
Sector
Industry
Phone
617-949-2680
Address
40 GUEST STREET, BOSTON, MA
Compare CUE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
0.7415 | 58.56M | 9.53M | -44.61M | -38.32M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-24 | Initiated | Jefferies | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Nov-21-22 | Initiated | Piper Sandler | Overweight |
| Jan-13-22 | Initiated | H.C. Wainwright | Buy |
| Jan-03-22 | Initiated | Craig Hallum | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Apr-09-20 | Initiated | Stifel | Buy |
| Jan-28-20 | Initiated | BTIG Research | Buy |
| Jan-22-20 | Initiated | JMP Securities | Mkt Outperform |
View All
Cue Biopharma Inc Stock (CUE) Latest News
Chart overlay techniques for tracking Cue Biopharma Inc.Weekly Profit Report & Daily Chart Pattern Signals - Newser
Technical signs of recovery in Cue Biopharma Inc.July 2025 Movers & Expert Approved Momentum Ideas - Newser
What indicators show strength in Cue Biopharma Inc.Trade Volume Summary & Safe Capital Investment Plans - Newser
Statistical indicators supporting Cue Biopharma Inc.’s strength2025 Top Decliners & Free High Return Stock Watch Alerts - Newser
Will Cue Biopharma Inc. see short term momentumMarket Sentiment Summary & Long-Term Safe Investment Ideas - Newser
Cue Biopharma Inc.’s volatility index tracking explainedExit Point & Consistent Return Investment Signals - Newser
Cue Biopharma Inc. stock prediction for this weekTrend Reversal & Safe Entry Momentum Tips - Newser
Visualizing Cue Biopharma Inc. stock with heatmapsMarket Risk Report & Real-Time Market Trend Scan - Newser
How to track smart money flows in Cue Biopharma Inc.Weekly Trade Recap & Weekly Return Optimization Alerts - Newser
Visual trend scoring systems applied to Cue Biopharma Inc.Bond Market & Short-Term Trading Opportunity Alerts - Newser
Does Cue Biopharma Inc. qualify in momentum factor screeningWeekly Profit Analysis & Weekly High Momentum Picks - Newser
Cue Biopharma (NASDAQ:CUE) Stock Price Down 1%What's Next? - MarketBeat
Sector ETF performance correlation with Cue Biopharma Inc.Quarterly Profit Review & Community Verified Watchlist Alerts - Newser
Real time scanner hits for Cue Biopharma Inc. explainedMarket Trend Summary & Consistent Income Trade Ideas - Newser
Can Cue Biopharma Inc. hit a new high this monthMarket Weekly Review & Weekly Momentum Picks - Newser
Intraday pattern recognizer results for Cue Biopharma Inc.2025 Earnings Impact & Verified Swing Trading Watchlists - Newser
What makes Cue Biopharma Inc. stock price move sharplyEarnings Overview Report & Capital Efficiency Focused Strategies - Newser
Chart based analysis of Cue Biopharma Inc. trendsStop Loss & Weekly High Return Opportunities - Newser
Real time pattern detection on Cue Biopharma Inc. stockSell Signal & Real-Time Volume Trigger Notifications - Newser
How to escape a deep drawdown in Cue Biopharma Inc.Weekly Trade Review & Real-Time Stock Movement Alerts - Newser
When is the best time to exit Cue Biopharma Inc.Portfolio Risk Summary & High Yield Equity Trading Tips - Newser
Regression analysis insights on Cue Biopharma Inc. performanceSwing Trade & Long-Term Safe Investment Ideas - Newser
What institutional flow reveals about Cue Biopharma Inc.IPO Watch & Weekly Top Stock Performers List - Newser
A | Can Cue Biopharma, Inc. disrupt its industryJuly 2025 Spike Watch & Fast Entry and Exit Trade Plans - Lancaster City Council
What’s the profit margin of Cue Biopharma Inc.Bull Run & Weekly Momentum Stock Picks - Lancaster City Council
Cue Biopharma Inc Stock (CUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):